Metastasis is the primary cause of cancer-related death \[[@CR1]\]. Even in tumors that are sensitive to radiotherapy or chemotherapy, metastasis is often the main reason of treatment failure \[[@CR2]\]. Metastatic tumors not only are difficult to treat with conventional surgery or radiotherapy due to their anatomically diffuse localization in different organs, but also, in most cases, are resistant to cytotoxic agents. Although some technological advances in the twentieth century in imaging and cancer cell identification have dramatically improved our understanding of cancer metastasis, the molecular mechanisms underlying cancer metastasis and chemoresistance are mostly unknown. Consequently, of over 200 anti-cancer drugs that have been approved for clinical administration, none specifically and effectively inhibits cancer metastasis.

The mechanisms underlying cancer metastasis are extremely complicated and involve multiple cell types and several key signaling pathways \[[@CR1]\]. A review focusing on the interactions between immune cells and tumor cells can be found in this issue of the *Chinese Journal of Cancer* (*CJC*) \[[@CR3]\]. More comprehensive discussion of the effect of tumor microenvironment on cancer metastasis can be found in another review article, also in this issue of the *CJC* \[[@CR4]\].

Recently, accelerating explorations in the field of cancer metastasis have revealed over 200 genes, in a variety of experimental scenarios, which promote cancer cell motility. A review article in this issue of the *CJC* discusses a collection of 150 important pro-metastatic genes and may be useful for big-data analyses \[[@CR5]\]. However, before we can better perceive and more effectively inhibit cancer metastasis, some critical issues must be better understood.

Pro-metastatic genes do not always associate with poor prognosis {#Sec2}
================================================================

When we analyzed the pro-metastatic genes using The Cancer Genome Atlas (TCGA) datasets \[[@CR5]\], we found that four genes---*JAM2*, *PPARGC1A*, *SIK2*, and *TRAF6*---have contradictory effects on patient overall survival in different types of cancer. In the original reports of these genes' pro-metastatic functions, *JAM2* was studied in melanoma \[[@CR6]\], *PPARGC1A* \[[@CR7]\] and *TRAF6* \[[@CR8]\] were studied in breast cancer, and *SIK2* was studied in ovarian cancer \[[@CR9]\]. When we analyzed the clear cell renal cell carcinoma and hepatocellular carcinoma patient cohorts to evaluate the prognostic value of mRNA levels of the four genes, we found that elevated expression was significantly associated with long overall survival (Fig. [1](#Fig1){ref-type="fig"}). Clearly, these four genes encode protective factors for patients with renal cancer and liver cancer. These findings suggest that more complicated mechanisms might underlie cancer metastasis in different tumor types. Furthermore, previous evaluation approaches might not always be appropriate for identifying the true causes of cancer metastasis.Fig. 1Survival curves of two cohorts of cancer patients separated by the mRNA levels of four genes. The data were retrieved from The Cancer Genome Atlas database. The survival curves were plotted using the Kaplan--Meier method and compared using the log-rank test. The median values were used as cutoff values to separate patients into high- or low-expression groups. *ccRCC* clear cell renal cell carcinoma, *HCC* hepatocellular carcinoma

Issues in developing anti-metastatic drugs {#Sec3}
==========================================

Over 200 anti-cancer drugs have been approved for clinical application. These drugs inhibit tumor cell proliferation, inhibit tumor angiogenesis, or enhance immune function. In the era of targeted therapy, some anti-cancer drugs have multiple effects, such as inhibiting tumor cell proliferation and tumor angiogenesis. Expectations have been high for personalized medicine, which uses genomic information to guide drug application; however, so far for most solid cancer patients, limited survival benefits have been achieved \[[@CR10], [@CR11]\]. The primary reason is that metastasis kills most of patients, and very few of these drugs inhibit cancer metastasis.

From a pharmaceutical point of view, many approaches to evaluate the anti-proliferation properties of candidate compounds have been applied with widely accepted standards, from screening the compound using 50% inhibitory concentration (IC~50~) in vitro to measuring tumor growth inhibition rate in vivo. These standardized pharmacologic tests have been routinely required by the U.S. Food and Drug Administration (FDA) for pre-clinical evaluation. However, the dilemma is that the FDA does not require that the drugs under approval show any anti-metastatic effects.

Multiple obstacles hamper the development of anti-metastatic drugs. First, pharmaceutical companies have few effective, high-throughput technologies to screen their compound library for potential anti-metastatic compounds. A recent pioneering study by Polireddy et al. \[[@CR12]\] using E-cadherin as a marker to identify inhibitors of cancer cell invasion was a credible attempt to address this issue. Second, most pharmaceutical companies have not developed standard techniques for using appropriate animal models for pre-clinical anti-metastatic assessment, whereas these models are well-established in academic laboratories \[[@CR13]--[@CR16]\]. Third, to better enable the development of anti-metastatic drugs, clinical trial designs might need to be adjusted to set metastasis-free survival as the primary endpoint. Obviously, more efforts are needed to overcome these obstacles, and high-throughput technologies should be developed and optimized to speed the pace of anti-metastatic drug development.

Single-cell metastasis and epithelial--mesenchymal transition {#Sec4}
=============================================================

Epithelial--mesenchymal transition (EMT) has been recognized as an important event to strengthen the metastatic ability of cancer cells. A review article discusses the functions of MTA3 as a master suppressor of EMT and metastasis \[[@CR17]\]. E-cadherin has been widely used as an epithelial marker in evaluating EMT. In this issue of the *CJC*, a novel role of E-cadherin as a sensitizer of chemoresistant prostate cancer cells by inhibiting Notch signaling is revealed \[[@CR18]\]. However, our understanding of the role of EMT in metastasis is based mainly on the evidence of single-cell motility. When cancer metastasis is caused by cancer cell clusters, EMT of the tumor cells is not necessary \[[@CR19], [@CR20]\]. In terms of forming metastatic lesions, cancer cell clusters are more aggressive than single cancer cells \[[@CR21]\]. Moreover, cancer cell clusters in circulation can better survive when they are enveloped by endothelial cells \[[@CR22]\]. Obviously, more appropriate in vitro and in vivo models for studying cell cluster mobility and metastasis should be developed.

In summary, better prevention and inhibition of cancer metastasis is currently limited by our insufficient understanding of its nature. However, we are confident that through multidisciplinary efforts and the development of more effective, high-throughput technologies to identify metastasis inhibitors, we can better predict, prevent, and treat cancer metastasis.
